PG Research Update — September 17, 2026
Updated Thesis
Procter & Gamble is a global consumer-staples leader selling daily-use products across beauty, grooming, health care, fabric and home care, and baby, feminine and family care in about 180 countries. Business quality is high because its brands, consumer insight, R&D, marketing scale and global distribution underpin leading category positions, including over 60% in blades and razors and over 35% in fabric care, while TTM gross, operating and net margins are 50.2%, 22.7% and 18.4%, respectively, and ROE is 29.8%. The investment debate is whether these strengths can overcome a maturing growth profile: revenue grew 1.5% year over year and earnings declined 17.1% year over year in the most recent quarter, while FY2027 organic-sales guidance is only 1%-3% amid roughly $1.0 billion after-tax input-cost headwinds.
The investment grade as of this refresh is B+ — above-average business quality. High-tier business, attractive-tier valuation, with 14.4% upside to $168.19 fair value but modest organic-growth guidance and no greater-than-30% upside.
Grade Change
In this research cycle, the investment grade for The Procter & Gamble Company moved from A- to B+. High-tier business, attractive-tier valuation, with 14.4% upside to $168.19 fair value but modest organic-growth guidance and no greater-than-30% upside.
Key Metrics at a Glance
- Revenue growth: +1.5% year over year
- Net margin: 18.4%
- Fair value upside: +14.4% to our estimate of $168
Current price: $147.04
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. The Procter & Gamble Company remains in our covered universe with a above-average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full PG research →](/stocks/PG)